Skip to main content
SpringerLink
Log in

Erlotinib

  • Chapter
  • First Online:
Book cover Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 184))

Abstract

The epidermal growth factor receptor (EGFR) has been implicated in a multiplicity of cancer-related signal transduction pathways like cellular proliferation, adhesion, migration, neoangiogenesis, and apoptosis inhibition, all of them important features of cancerogenesis and tumour progression. Its tyrosine kinase activity plays a central role in mediating these processes and has been intensely studied to exploit it as a therapeutic target. Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cell lung cancer (NSCLC) and pancreatic cancer with emphasis on the approved small molecule erlotinib. Its clinical applications, evidence-based efficacy, and toxicity as well as predictive markers of response are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 259.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alroy I, Yarden Y (1997) The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83–86

    Article  PubMed  CAS  Google Scholar 

  • Arteaga CL (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29 (5 Suppl14):3–9

    Google Scholar 

  • Bezjak A, Tu D, Seymour L et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 24:3831–3837

    Article  PubMed  CAS  Google Scholar 

  • Birk D, Gansauge F, Gansauge S (1999) Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis. Int J Pancreatol 25:89–96

    Article  PubMed  CAS  Google Scholar 

  • Boeck S, Hausmann A, Reibke R et al (2007) Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 18:1109–1111

    Article  PubMed  CAS  Google Scholar 

  • Brabender J, Danenberg KD, Metzger R et al (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7: 1850–1855

    PubMed  CAS  Google Scholar 

  • Bramhall SR, Schulz J, Nemunaitis J (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167

    Article  PubMed  CAS  Google Scholar 

  • Buckley AF, Burgart LJ, Sahai V et al (2008) Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 129: 245–251

    Article  PubMed  Google Scholar 

  • Burris HA 3rd, Moore MJ, Andersen J (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  • Cedrés S, Prat A, Martínez P et al (2009) Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer, in Press

    Google Scholar 

  • Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  PubMed  CAS  Google Scholar 

  • Chiang D, Villanueva A, Peix J (2008) Focal VEGFA amplifications and molecular classification of hepatocellular carcinoma. Cancer Res 68: 6779–6788

    Article  PubMed  CAS  Google Scholar 

  • Clark GM, Zborowski DM, Santabarbara P et al (2006) Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 7:389–394

    Article  PubMed  CAS  Google Scholar 

  • Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M (2006) Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 51:89–96

    Article  PubMed  Google Scholar 

  • Duffy A, Kortmansky J, Schwartz GK et al (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19:86–91

    Article  PubMed  CAS  Google Scholar 

  • El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750

    Article  PubMed  CAS  Google Scholar 

  • Epelbaum R, Schnaider J, Gluzman A (2007) Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. ASCO Gastro­intestinal Cancer Symposium, Orlando, FL, 19–21 January 2007

    Google Scholar 

  • Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237–2246

    Article  PubMed  CAS  Google Scholar 

  • Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 25:1545–1552

    Article  PubMed  CAS  Google Scholar 

  • Giaccone G (2004) The role of gefitinib in lung cancer treatment. Clin Cancer Res 10:4233s–4237s

    Google Scholar 

  • Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892–5899

    Article  PubMed  CAS  Google Scholar 

  • Huether A, Hopfner M, Sutter AP et al (2006) Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 12:5160–5167

    PubMed  CAS  Google Scholar 

  • Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354

    Article  PubMed  CAS  Google Scholar 

  • Iannitti D, Dipetrillo T, Akerman P (2005) Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28:570–575

    Article  PubMed  CAS  Google Scholar 

  • Kindler H, Niedzwiecki D, Hollis D (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (Pts) with advanced pancreatic cancer (PC): a preliminary analysis of cancer and leukemia group B (CALGB) 80303. J Clin Oncol 25(Suppl 18):4508

    Google Scholar 

  • Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158

    Article  PubMed  CAS  Google Scholar 

  • Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787–4792

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Ricci S, Mazzaferro V et al, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  PubMed  CAS  Google Scholar 

  • Lynch TJ Jr, Kim ES, Eaby B (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610–621

    Article  PubMed  CAS  Google Scholar 

  • Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non–small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865

    Article  PubMed  CAS  Google Scholar 

  • Mok T, Wu Y-L, Thongprasert S et al (2008) Phase III, randomised, open-label, first-line study of gefitinib (G) vs. carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Ann Oncol 19(Suppl 8):viii1

    Google Scholar 

  • Moore MJ, Goldstein D, Hamm J (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

    Article  PubMed  CAS  Google Scholar 

  • Moore MJ, Hamm J, Dancey J (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296–3302

    Article  PubMed  CAS  Google Scholar 

  • Natale RB (2004) Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Sem Oncol 31(3 Suppl 9):23–30

    Article  CAS  Google Scholar 

  • Neuhaus P, Riess H, Post S et al (2008) CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26:abstr. LBA4504

    Google Scholar 

  • Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15

    Article  Google Scholar 

  • Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500

    Article  PubMed  CAS  Google Scholar 

  • Parkin DM, Bray F, Ferlay J (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  • Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–13311

    Article  PubMed  CAS  Google Scholar 

  • Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556–2568

    Article  PubMed  CAS  Google Scholar 

  • Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 (Suppl):abstr 4508

    Google Scholar 

  • Pérez-Soler R, Chachoua A, Hammond LA et al (2004) Determants of tumour response and survival with erlotinib in patients with non-small-cell lung cancer: a randomized trial. J Clin Oncol 22:3238–3247

    Article  PubMed  CAS  Google Scholar 

  • Pérez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor inhibitors in lung cancer. Clin Lung Cancer 8(Suppl 1): S7–14

    Google Scholar 

  • Philip PA, Benedetti J, Fenoglio-Preiser C (2007) Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (Pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC) SWOG S0205 study. J Clin Oncol 25(Suppl 18):abstr LBA4509

    Google Scholar 

  • Philip PA, Mahoney MR, Allmer C (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657–6663

    Article  PubMed  CAS  Google Scholar 

  • Schneider G, Hamacher R, Eser S et al (2008) Molecular biology of pancreatic cancer – new aspects and targets. Anticancer Res 28(3A): 1541–1550

    PubMed  CAS  Google Scholar 

  • Saif MW, Merikas I, Tsimboukis S et al (2008) Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 9:267–274

    PubMed  Google Scholar 

  • Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Article  PubMed  CAS  Google Scholar 

  • Sandler AB (2006) Nondermatologic adverse events associated with anti-EGFR therapy. Oncology 20(5 Suppl 2):35–40

    PubMed  Google Scholar 

  • Shapiro J, Marshall J, Karasek P (2005) G17DT+gemcitabine (Gem) versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol 23(Suppl 16):4012

    Google Scholar 

  • Shepherd FA, Pereira JR, Ciuleanu T et al for the National Cancer Institute of Canada Clinical Trails Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Article  Google Scholar 

  • Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 20: 2607–2615

    Article  Google Scholar 

  • Tang PA, Tsao MS, Moore MJ (2006) A review of erlotinib and its clinical use. Expert Opin Pharmacother 7:177–193

    Article  PubMed  CAS  Google Scholar 

  • Thomas MB, Chadha R, Glover K (2007) Phase 2 study of erlotinib in patients with unresect­able hepatocellular carcinoma. Cancer 110: 1059–1067

    Article  PubMed  CAS  Google Scholar 

  • Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27: 843–850

    Article  PubMed  CAS  Google Scholar 

  • Tsao M-S, Sakurada A, Cutz J-C et al (2005) Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 353: 133–144

    Article  PubMed  CAS  Google Scholar 

  • Van Cutsem E, Van de Velde H, Karasek P (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22: 1430–1438

    Article  PubMed  CAS  Google Scholar 

  • Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, A117

    Google Scholar 

  • Villanueva A, Newell P, Chiang D (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55–76

    Article  PubMed  CAS  Google Scholar 

  • Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913–3921

    Article  PubMed  CAS  Google Scholar 

  • Xiong HQ, Abbruzzese JL (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29(Suppl 14):31–37

    Article  PubMed  CAS  Google Scholar 

  • Zhu C-Q, da Cunha Santos G, Ding K et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 26:4268–4275

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Thoracic Diseases, University of Heidelberg, Amalienstraße 5, 69126, Heidelberg, Germany

    M. Steins

Authors
  1. M. Steins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Geißler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Steins .

Editor information

Editors and Affiliations

  1. Medizinische Klinik III, SLK-Kliniken Heilbronn GmbH, Am Gesundbrunen 20-26, Heilbronn, 74078, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Steins, M., Thomas, M., Geißler, M. (2010). Erlotinib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 184. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01222-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01222-8_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01221-1

  • Online ISBN: 978-3-642-01222-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation